All In Biotech

NDA 204096 · Astellas

Astagraf Xl

Tacrolimus · Oral

Last checked: Nov 20, 2026Latest source record: Sep 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jul 19, 2013

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,405

234 Phase 3, 122 recruiting

FAERS reports

353

192 serious, 40 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS • Increased risk for developing serious infections and malignancies with ASTAGRAF XL ® or other immunosuppressants that may lead to hospitalization or death. [see Warnings and Precautions ( 5.1 , 5.2 )] • Increased mortality in female liver transplant patients with ASTAGRAF XL. ASTAGRAF XL is not approved for use in liver transplantation. [see Warnings and Precautions ( 5.3 )] WARNING: MALIGNANCIES AND SERIOUS INFECTIONS IN TRANSPLANT PATIENTS; AND INCREASED MORTALITY IN FEMALE LIVER TRANSPLANT PATIENTS See full prescribing information for complete boxed warning. • Increased risk for developing serious infections and malignancies with ASTAGRAF XL or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 ) • Increased mortality in...

What it is approved for

From the label in effect Jan 14, 2026.

ASTAGRAF XL ® is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact [see Use in Specific Populations ( 8.4 ) and Clinical Studies ( 14.1 ), ( 14.2 )]. ASTAGRAF XL is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact. ( 1 , 8.4 , 14.1 , 14.2 )

Mechanism: Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed and the phosphatase activity of calcineurin is inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL‑2, IL-3, IL-4, IL-5,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ASTAGRAF XL · TACROLIMUS EQ 5MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ASTAGRAF XL · TACROLIMUS EQ 0.5MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • ASTAGRAF XL · TACROLIMUS EQ 1MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tacrolimus" as an intervention, any sponsor and status, largest first.

All 1,405 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death27
  • inappropriate schedule of drug administration20
  • diarrhoea15
  • hospitalisation15
  • off label use14
  • malaise13
  • pneumonia13
  • nausea11
  • treatment noncompliance11
  • kidney transplant rejection10
  • pyrexia10
  • vomiting10

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20131
201446
201557
201659
201757
201845
201910
202013
20216
202211
202312
202421
20256
20268

Recalls

1 FDA enforcement reports for this application.

  • Dec 23, 2024 · Class I · Ongoing

    Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Astagraf XL (Tacrolimus)

2024 spending

$498K

Beneficiaries

139

703 claims

Per beneficiary

$3,580

$9.05 per unit

View as table
YearSpending
2020$481,694
2021$512,144
2022$512,326
2023$448,011
2024$497,646

Part B: Astagraf XL (Tacrolimus) · HCPCS J7508

2024 spending

$2.6M

Beneficiaries

472

4,894 claims

Per beneficiary

$5,535

2024 ASP limit $0.56 per unit

View as table
YearSpending
2020$5,383,228
2021$4,208,205
2022$3,508,023
2023$3,009,261
2024$2,612,579

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,850 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.